Vaishali Pharma Limited, engaged in production and marketing of a diverse range of pharmaceutical products, announced its unaudited Financial Results for Q2 FY24. The company posted total income during Q2 FY24 at Rs. 12.86 crore and EBITDA at Rs. 2.95 crore. Profit After Tax was at Rs. 1.70 crore.

Commenting on the performance, Atul Vasani, Chairman and Managing Director of Vaishali Pharma Limited said, “We are pleased to present the results for H1 of FY24. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success.

Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide.”